CSIMarket
 
Bridgebio Pharma Inc   (BBIO)
Other Ticker:  
 

Bridgebio Pharma Inc

Officers & Directors






  News about Bridgebio Pharma Inc Key Personnel

BridgeBio Pharma's Strategic Offering Sets the Stage for Genetic Disease and Cancer Breakthroughs

BridgeBio Pharma Announces Pricing of Public Offering of Common Stock - A Strategic Move to Boost Genetic Disease and Cancer Research
PALO ALTO, Calif., March 5, 2024 - BridgeBio Pharma, Inc. (Nasdaq: BBIO), a leading commercial-stage biopharmaceutical company dedicated to genetic diseases and cancers, has recently announced the pricing details of a public offering of its common stock. This underwritten public offering consists of 8,620,690 shares at a price of $29.00 per share. BridgeBio has also granted the underwriters an option to purchase an additional 1,293,103 shares on the same terms. With an expected gross proceeds of approximately $250.0 million, this move is aimed at supporting their ongoing ...






BBIO Management Effectiveness BBIO Revenue per Employee BBIO Income per Employee


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com